Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Victor Marder, M.D.
Victor Marder, M.D.


Cancer/Medical Oncology
Pediatric Hematology/Oncology

General Information:

English, French


Professor, Department of Pediatrics
Physician, Department of Neurology
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Internal Medicine, Strong Memorial Hospital, 1965 - 1966
Internal Medicine, Strong Memorial Hospital, 1960 - 1961
Internal Medicine, Johns Hopkins University School of Medicine, 1959 - 1960
Medical Degree:
M.D., Johns Hopkins University School of Medicine, 1959


Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 1972

Contact Information:

(310) 825-4469 Office
(310) 825-4285 Laboratory
(310) 794-1663 Outpatient appointments
(310) 794-1195 Neurology information and patient appointments
(310) 825-6185 Pediatrics information and referral
(310) 206-5737 Pediatrics admissions
(310) 825-0867 Pediatrics outpatient appointments
(310) 206-6931 or (310) 206-6909 UCLA Oncology Center information and patient appointments

Practice Information:

Clinical Interest(s):
General Hematology

Scientific Interest(s):

Dr. Victor Marder's research is directed towards establishing a novel and effective treatment of acute stroke. For patients whose stroke is caused by a clot, which blocks a major artery to the brain, Marder is developing therapy with an agent, plasmin, which has the potential to dissolve the clot without risk of bleeding complications. A federal grant from the National Institutes of Health funds this work, which is being done in collaboration with the neurology department, to perform a Phase I study in patients with acute stroke.

In collaboration with colleagues in the hematology/oncology division, department of neurology, and basic scientists at Bayer Health Corp. (Research Triangle, North Carolina), Marder is establishing an animal model of embolic stroke, in order to compare plasmin with the standard of care agent, TPA. These experiments will evaluate the relative efficacy and safety of plasmin and assist in determining an appropriate dosage of plasmin to be utilized in the subsequent Phase I study in human stroke.

Selected Cancer-Related Publications:

Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106(12): 3791-6.

Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2003; 101(8): 3002-7.